Oncology Views & Analysis

Views & Analysis

Oncology

Interview at ESMO 2025 with EVERSANA's Barry Vucsko

ESMO25: Acceleration, accessibility, and accuracy, with Barr...

At ESMO25, pharmaphorum spoke with Barry Vucsko, Senior VP of Strategic Development, Agency Services, for the EVERSANA Oncology Centre of Excellence.

Oncology

Interview at ESMO 2025 with Liam Tremble

ESMO25: Transforming the cancer immunotherapy field, with Po...

Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.

Oncology

ESMO25: On getting ahead of cancer, with J&J's Henar Hevia &...

In conversation with Johnson & Johnson experts at ESMO 2025, discussing T-cell-redirecting bispecific antibodies and the future of immunotherapy.

Oncology

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.

Oncology

pharmaphorum podcast Episode 211, ESMO25: Boehringer Ingelheim

ESMO25: Patient-centric oncological futures with Boehringer ...

On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.

Oncology

ESMO 2025 commences: ADCs, AI, and Asia

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

ESMO25: Acceleration, accessibility, and accuracy, with Barr...

ESMO25: Transforming the cancer immunotherapy field, with Po...

ESMO25: On getting ahead of cancer, with J&J's Henar Hevia &...

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

ESMO25: Patient-centric oncological futures with Boehringer ...

ESMO 2025 commences: ADCs, AI, and Asia

UK puts £80m behind dementia diagnosis push

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks